Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

摘要: Abstract We studied the safety and immunogenicity in healthy adults of an 11-valent pneumococcal conjugate vaccine. Capsular polysaccharides (PS) serotypes 1, 4, 5, 7F, 9V, 19F 23F were conjugated to tetanus toxoid, 3, 6B, 14 18C diphtheria toxoid. Ten subjects received vaccine with other ten without aluminium hydroxide adjuvant. The reference was a marketed 23-valent PS Safety data recorded over 5 days after immunisation. IgG antibody concentrations, avidity subclass distribution measured by EIA. induced more local adverse effects than or All vaccines evoked significant increases all specific antigens. Both antibodies mainly 2 subclass, adjuvanted increased avidity. This first administration, man, mixed protein carrier demonstrated its ability induce immune response effects, enabling further study on use paediatric populations.